Eloxx Q2 Loss Widens; Exaluren Phase 2b Trial Set To Begin In Q3 2026

Eloxx Pharmaceuticals (ELOX) rose 20% after FDA cleared its Phase 2b trial for exaluren. Vogenx (VOGX) gained 14% post-IPO. Arcturus (ARCT) advanced 21% on pipeline updates. Zhengye (ZYBT) +7% after Nasdaq compliance. Greenwich (GLSI) +10% on extended lock-up. HeartSciences (HSCS) +8% after $1M investment. AC Immune (ACIU) +8% on Phase 1 data.

Eloxx Pharmaceuticals (Nasdaq: ELOX) reported Q2 2026 results and a business update. It completed a $66.0 million underwritten public offering and uplisted to Nasdaq (symbol ELOX). Cash was $62.0 million at June 30, 2026. Phase 2b exaluren in nonsense mutation Alport syndrome is expected to start Q3 2026; ADPKD trial planned for 2027. Net loss was $4.5 million.

Eloxx Pharmaceuticals, Inc. (ELOX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 d167833dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Eloxx Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update • Completed underwritten public offering with gross proceeds of $66.0 million and uplisting to the Nasdaq Capital Market, sign

U.S. markets declined as Iran sanctions and elevated gasoline prices impacted consumer spending. Walmart's shares fell 9.2% after reporting slow sales growth and warning of higher fuel costs. The Dow Jones dropped 1.32%, the S&P 500 lost 0.87%, and the Nasdaq fell 1%. The 30-year U.S. Treasury yield hit 5.25%, its highest since 2007, signaling investor concern. Bitcoin briefly surged 11.5% before yields rebounded. Fed minutes showed dissent over rate hikes, with inflation and borrowing costs as

Synopsys (SNPS) is expected to report fiscal Q3 earnings on August 26, 2026. The company has shown two consecutive quarters of beating earnings estimates and raising guidance, with revenue up 41.98% year-over-year. Management has guided for continued growth in Q3. The company's expanding margins and debt reduction are noted as positive factors. Analysts are generally bullish, with an average price target of $561.03. Cadence Design Systems (CDNS) is mentioned as a comparable, but with slower grow

SAN JUAN BASIN ROYALTY TRUST (SJT) filed an SEC Form 8-K — Results of Operations and Financial Condition. 8-K 1 august_2026_8-k.htm 8-K 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report August 21, 2026 SAN JUAN BASIN ROYALTY TRUST (Exact name of Regi